{"id":"NCT03162055","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","officialTitle":"A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-25","primaryCompletion":"2018-05-04","completion":"2018-05-04","firstPosted":"2017-05-22","resultsPosted":"2019-05-22","lastUpdate":"2019-05-22"},"enrollment":1119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease COPD"],"interventions":[{"type":"DRUG","name":"Glycopyrronium/Formoterol Fumarate","otherNames":[]},{"type":"DRUG","name":"umeclidinium/vilanterol","otherNames":[]}],"arms":[{"label":"Experimental","type":"EXPERIMENTAL"},{"label":"Active comparator","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.","primaryOutcome":{"measure":"Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks","timeFrame":"From Baseline (Day 1) up to 24 weeks","effectByArm":[{"arm":"Glycopyrronium/Formoterol Fumarate","deltaMin":82.4,"sd":11.2},{"arm":"Umeclidinium/Vilanterol","deltaMin":169.6,"sd":11.2}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9974"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":107,"countries":["United States","Bulgaria","Canada","France","Hungary","Russia","Ukraine"]},"refs":{"pmids":["31267366"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":552},"commonTop":["Headache","Nasopharyngitis","Viral upper respiratory tract infection","Chronic obstructive pulmonary disease","Back pain"]}}